XLV - Health Care Select Sector SPDR® Fund
| Previous Close | 82.41 |
| Open | 82.67 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 81.18 - 82.72 |
| 52 Week Range | 74.45 - 91.79 |
| Volume | 8,904,776 |
| Avg. Volume | 10,213,482 |
| Net Assets | 15.32B |
| NAV | 81.24 |
| PE Ratio (TTM) | N/A |
| Yield | 1.53% |
| YTD Return | -1.20% |
| Beta (3y) | 0.93 |
| Expense Ratio (net) | 0.14% |
| Inception Date | 1998-12-16 |
Yahoo Finance Video•8 days agoYahoo Finance Live: Midday Movers - Apr 17th, 2018
Yahoo Finance's LIVE stock market coverage and analysis.
- CNBC Videos•27 days ago
First quarter ETF leaders and laggards
CNBC's Mike Santoli takes a look at ETF performance in the first quarter.
- Market Realist•6 days ago
Another Indicator Signaling Rising Inflation
The US Bureau of Labor Statistics releases a monthly report that tracks price trends in wholesale markets. Industries from the manufacturing sector (XLI) are surveyed for changes in input prices, and this survey data is used to construct the PPI (Producer Price Index). The survey comprises questions on raw material prices, production levels, and finished goods.
- Market Realist•7 days ago
3.2 Million Americans Quit Their Jobs in February
The “Job Openings and Labor Turnover Survey” (or JOLTS) data for February was reported on April 13, and it contains information about job openings and total separations. The total number of separations includes layoffs, retirements, and voluntary quitting. As per the latest JOLTS report, the total separations for February was 5.2 million at a rate of 3.5% of the total workforce and a decrease from the January reading of 5.9 million and 4.1%, respectively.
- Benzinga•7 days ago
The Size Effect Is Working With Health Care ETFs
Investors solely focusing on large-cap health care stocks and exchange-traded funds this year are likely disappointed. Entering Tuesday, the Health Care Select Sector SPDR (NYSE: XLV), the largest ETF by assets tracking the sector, was up just 0.2 percent year-to-date. For investors willing to take on a little more risk with their health care investments, noteworthy is the fact that the size effect is working with health care stocks this year.
- Market Realist•9 days ago
What to Expect from Johnson & Johnson’s 1Q18 Earnings
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17Johnson & Johnson’s estimates
- Barrons.com•12 days ago
Medical-Device Makers Need Robust Results
As we approach another earnings season, medical-device companies look poised to report quarters in line with expectations. At least that's the warning from Morgan Stanley's David Lewis. He writes that first-quarter fundamentals look encouraging for the group, given a favorable utilization environment at the start of the year—and a more severe flu season than usual that could serve as another tailwind. Among large-caps in the space, Lewis says Intuitive Surgical (ISRG), Becton Dickinson (BDX), and Zimmer Biomet (ZBH) have a good chance of beating expectations.
- Investopedia•15 days ago
Why J&J’s Fallen Stock Is Still Too Pricey
Johnson & Johnson stock has had a terrible 2018—and the outlook for revenue growth remains weak.
- Market Realist•16 days ago
How 1Q18 Treated Pharmaceutical ETFs
Pharmaceutical ETFs are securities that are publicly traded on stock markets and designed for investors who don’t have the capacity to hold many stocks but are willing to diversify their investments within the pharmaceutical sector.
- Barrons.com•16 days ago
Is Health Care Immune to the Market's Ills?
While it’s been easy to lose sight of individual sectors amid the market’s recent volatility, there’s been no shortage of health-care news lately, including Incyte’s (INCY) 20% plunge on Friday, after its cancer treatment epacadostat failed in a late-stage trial. Merck (MRK), whose blockbuster drug Keytruda was being tested with epacadostat, bounced back quickly: The shares are higher on Monday, thanks to upbeat data from a lung cancer trial. Meanwhile AbbVie (ABBV) is climbing on news that its rheumatoid arthritis drug showed positive results in a late-stage trial.
- Market Realist•16 days ago
Which Sector Posted Major Job Gains in March 2018?
The ADP March jobs report was published on April 4, 2018. It offered a deeper insight into employment trends across different sectors in the US employment market. ADP and Moody’s analytics prepare this monthly report.
- Investopedia•18 days ago
Top 3 Healthcare Stocks for 2018
These three healthcare stocks were strong in 2017, and the upward trend may continue this year.
- Benzinga•20 days ago
Finding Value In Health Care ETFs
The health care sector has performed only slightly better than the broader market this year. For example, the Health Care Select Sector SPDR (NYSE: XLV ) is off 0.6 percent, while the S&P 500 is lower ...
- Market Realist•21 days ago
Can HOLX Stock Rebound from Its Recent Lows?
Investor Update: Hologic's Recent Partnerships, Product Launches
- Market Realist•21 days ago
What’s behind Edwards Lifesciences’ Stock Rise?
Recent Developments at Edwards Lifesciences
- Market Realist•22 days ago
Johnson & Johnson Stock on March 29, 2018
Analyzing Johnson & Johnson’s Stock and Valuations in March 2018A look at Johnson & Johnson
Market Realist•26 days agoDiscussing BDX’s Recent Stock Price Performance
BDX's March 2018 Performance, Recommendations, and Updates
InvestorPlace•27 days agoThe Analysts Are Right About Teladoc Inc — It’s a Buy!
The healthcare sector, as measured by the Health Care Select Sector SPDR ETF (NYSEARCA:XLV), is down 1.5% so far in 2018, but even as the group as a whole struggles one of my favorite NexGen healthcare names is up more than 20%: Teladoc Inc (NYSE:TDOC). Teladoc is the leader in the emerging telehealth industry. In the future, the days of spending hours in a doctor’s office only for them to tell you that you have a sinus infection and need some antibiotics will be non-existent.
- Market Realist•27 days ago
What Analysts Recommend for Merck in March 2018
What Analysts Recommend for Merck in March 2018
- Market Realist•last month
Analysts’ Recommendations for Incyte in March 2018
Who’s Watching Incyte Corporation in March 2018?
- Motley Fool•last month
How to Invest in Healthcare Stocks the Easy Way
Here are several smart ways to invest in the companies that keep people healthy.
- Market Realist•last month
Discussing Teva’s Recent Stock Performance
On March 20, 2018, Teva Pharmaceutical (TEVA) ended the trading day at a closing price of $17.68. Recently, on February 15, 2018, TEVA stock registered a rise of ~10.5% triggered by the news of an investment of $358 million in the company by Berkshire Hathaway. This news led to the market’s gaining some confidence in the troubled stock, as Berkshire Hathaway investments have been synonymous with value investments.
- Market Realist•last month
Why the US Workforce’s Quit Rate Has Remained High
January’s JOLTS (Job Openings and Labor Turnover Survey) data, which contains information about job openings and total separations, was reported on March 16. The separation total includes layoffs, retirements, and voluntary quits. Total separations in January stood at 5.9 million, representing 4.1% of the total workforce and a minor increase from the December reading of 5.1 million.
Market Realist•last monthUnitedHealth Group’s Recent Stock Performance
UnitedHealth Group's Management Changes and Key Developments
